Company intelligence / Profile preview
ClostraBio
Chicago, Illinois, United Statesclostrabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ClostraBio published breakthrough research in Nature Biomedical Engineering demonstrating that polymeric nanoscale micelles can effectively restore intestinal homeostasis in mouse models of colitis and peanut allergy. CLB101™, the company's lead ingredient, completed toxicology studies published in the International Journal of Toxicology with GRAS (Generally Recognized as Safe) designation. CLB101™ launched commercially in September 2025 through a healthcare practitioner-focused dietary supplement partner.
- Therapeutic areas
- ImmunologyGastroenterology
- Modalities
- Live biotherapeutic product therapyNanoparticlePolymer-drug conjugate therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Portal Innovations
Beyond the preview
Go deeper on ClostraBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ClostraBio.